Research Results from University Hospital Update Knowledge of Pharmaceutics [Pharmacogenomics of 3,4-Methylenedioxymethamphetamine (MDMA): A Narrative Review of the Literature].

A recent report from University Hospital in Angers, France discusses the potential use of 3,4-Methylenedioxymethamphetamine (MDMA) in treating post-traumatic stress disorders (PTSD) and substance use disorders. The research highlights the importance of pharmacogenomics in guiding MDMA treatment by identifying individuals with genetic predispositions that affect their response to the drug. The study emphasizes the need for large-scale pharmacogenomics studies to optimize the therapeutic use of MDMA and minimize its risks. Further research is required to investigate the genetic variants and genes involved in MDMA metabolism and pharmacodynamics. [Extracted from the article]